Ovid Therapeutics: A Fast Growing Penny Stock to Watch
ByAinvest
Saturday, Jan 31, 2026 9:11 pm ET1min read
OVID--
Ovid Therapeutics (OVID) is a biopharmaceutical company developing medicines for epilepsies and seizure-related disorders. Analysts recommend it as one of the best fast-growing penny stocks to buy, with a price target of $4. The company announced successful Phase 1 results for OV350, its first direct activator of the KCC2 transporter, with a favorable safety and tolerability profile. Ovid plans to advance its oral KCC2 portfolio, with OV4071 expected to initiate Phase 1/1b clinical trials in Q2 2026 for treating psychoses associated with neurodegenerative conditions.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet